PR Newswire
MILWAUKEE
, Nov. 14, 2025 /PRNewswire/ — The Ademi Firm is investigating Repare (Nasdaq: RPTX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XenoTherapeutics, Inc.
Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.
In the transaction, Repare shareholders will receive an estimated $1.82 per share in cash at closing, based on the company’s current estimates. The final payment amount will be determined by Repare’s cash balance at closing after deducting transaction costs and outstanding liabilities. Additionally, shareholders will receive one non-transferable contingent value right (CVR) per share, entitling them to portions of future proceeds from existing partnerships and potential asset dispositions. The CVRs provide varying percentages of net proceeds from partnerships with Bristol-Myers Squibb, Debiopharm and DCx Biotherapeutics, ranging from 90% to 75% depending on timing over a 10-year period.
Repare insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Repare by imposing a significant penalty if Repare accepts a competing bid. We are investigating the conduct of the Repare board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi & Fruchter LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302616105.html
SOURCE Ademi LLP
